FGFR-1 beta Protein, Human (HEK293, hFc)

Customer Review

Based on 1 Customer Validation

FGFR-1 beta is a member of the FGFR family that interacts with fibroblast growth factors and regulates mitosis and differentiation. It specifically binds acidic and basic fibroblast growth factors and is involved in limb induction. FGFR-1 beta Protein, Human (HEK293, hFc) is the recombinant human-derived FGFR-1 beta protein, expressed by HEK293 , with C-hFc labeled tag.

For research use only. We do not sell to patients.
  • Species: Human
  • Source: HEK293
  • Storage:
    Stored at -20°C for 2 years from date of receipt. After reconstitution, it is stable at 4°C for 1 week or -20°C for longer (with carrier protein). It is recommended to freeze aliquots at -20°C or -80°C for extended storage.
  • Biological Activity
  • Technical Parameters
  • Product Properties
  • Documentation
  • Help & FAQs

Biological Activity

Description

FGFR-1 beta is a member of the FGFR family that interacts with fibroblast growth factors and regulates mitosis and differentiation. It specifically binds acidic and basic fibroblast growth factors and is involved in limb induction. FGFR-1 beta Protein, Human (HEK293, hFc) is the recombinant human-derived FGFR-1 beta protein, expressed by HEK293 , with C-hFc labeled tag.

Background

The FGFR-1 beta protein is a highly conserved member of the fibroblast growth factor receptor (FGFR) family, sharing a similar amino acid sequence with other members. FGFR family members exhibit different affinities for ligands and are distributed across various tissues. The full-length protein consists of an extracellular region with three immunoglobulin-like domains, a hydrophobic membrane-spanning segment, and a cytoplasmic tyrosine kinase domain. The extracellular portion interacts with fibroblast growth factors, initiating downstream signals that regulate mitogenesis and differentiation. FGFR-1 beta specifically binds to both acidic and basic fibroblast growth factors and plays a role in limb induction. Mutations in this gene have been associated with several syndromes and disorders, including Pfeiffer syndrome, Jackson-Weiss syndrome, Antley-Bixler syndrome, osteoglophonic dysplasia, and autosomal dominant Kallmann syndrome 2. Chromosomal aberrations involving this gene are linked to stem cell myeloproliferative disorder and stem cell leukemia lymphoma syndrome. Various alternatively spliced variants encoding different protein isoforms have been identified, although not all variants have been fully characterized. The FGFR-1 beta protein exhibits ubiquitous expression in multiple tissues, including the ovary, fat, and 25 other tissues.

Verified Bioactivity

1.This product does not contain protein kinase domain.
2.Measured by its ability to inhibit FGF acidic-dependent proliferation of NIH-3T3 mouse fibroblast cells. The ED50 for this effect is 1.096 ng/mL in the presence of 1ng/mL human FGF-1, corresponding to a specific activity is 9.12×10^5 units/mg.

MCE Validation Data

  • Purity - SDS-PAGE

    Purity - SDS-PAGE

    ≥ 90%, as determined by reducing SDS-PAGE.

Technical Parameters

  • Species Human
  • Source HEK293
  • Tag C-hFc
  • Accession
  • Gene ID
  • Molecular Construction
    • N-term
    • FGFR-1 beta (R22-E285)
      Accession # NP_075594.1
    • hFc
    • C-term
  • Protein Length

    Partial Extracellular Domain

  • Synonyms

    FGFR1; H3; Prev. FLT2; H5; Prev. KAL2; Heparin-Binding Growth Factor Receptor; BFGFR; Fibroblast Growth Factor Receptor; CEK; Receptor Protein-Tyrosine Kinase; FLG; FMS-Like Tyrosine Kinase 2; Basic Fibroblast Growth Factor Receptor 1; Hydroxyaryl-Protein

  • AA Sequence

    RPSPTLPEQDALPSSEDDDDDDDSSSEEKETDNTKPNPVAPYWTSPEKMEKKLHAVPAAKTVKFKCPSSGTPNPTLRWLKNGKEFKPDHRIGGYKVRYATWSIIMDSVVPSDKGNYTCIVENEYGSINHTYQLDVVERSPHRPILQAGLPANKTVALGSNVEFMCKVYSDPQPHIQWLKHIEVNGSKIGPDNLPYVQILKTAGVNTTDKEMEVLHLRNVSFEDAGEYTCLAGNSIGLSHHSAWLTVLEALEERPAVMTSPLYLE

  • Predicted Molecular Mass

    55.5 kDa

  • Molecular Weight

    Approximately 98 kDa, based on SDS-PAGE under reducing conditions.

  • Glycosylation

    Yes

  • Purity

    ≥ 90%, as determined by reducing SDS-PAGE.

Product Properties

Appearance

Lyophilized powder.

Formulation

Lyophilized from a 0.22 μm filtered solution of 20 mM PB, 150 mM NaCl, pH 7.4.

Endotoxin Level

<1 EU/μg, determined by LAL method.

Reconstitution

It is not recommended to reconstitute to a concentration less than 100 μg/mL in ddH2O. For long term storage it is recommended to add a carrier protein (0.1% BSA, 5% HSA, 10% FBS or 5% Trehalose).

Storage & Stability

Stored at -20°C for 2 years from date of receipt. After reconstitution, it is stable at 4°C for 1 week or -20°C for longer (with carrier protein). It is recommended to freeze aliquots at -20°C or -80°C for extended storage.

Shipping

Room temperature in continental US; may vary elsewhere.

Calculators

Reconstitution Calculator

Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration

Volume (to add to vial) Volume (to add to vial)
=
Mass (in vial) Mass (in vial)
÷
Desired Reconstitution Concentration Desired Reconstitution Concentration
Dilution Calculator

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

Concentration (start) Concentration (start)
×
Volume (start) Volume (start)
=
Concentration (final) Concentration (final)
×
Volume (final) Volume (final)
The Specific Activity Calculator Equation
  • Specific Activity (Unit/mg)
  • Biological Activity (ED50)

Specific Activity (Unit/mg) = 106 ÷ Biological Activity (ED50)

Specific Activity (Unit/mg) Specific Activity (Unit/mg)
Unit/mg
= 106 ÷
Biological Activity (ED50) Biological Activity (ED50)
106 ÷
ng/mL
MOQ
Minimum order quantity
100 mg

Get Quote In-stock

Other size
Get Quote
Please select quantity
Amount: USD 0.00